Improvement in Beta-Cell Function Observed after Three Years of BYETTA(R) Therapy

Amylin and Lilly announced the results of another study, comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy….

After three years of treatment, both therapies reduced A1c similarly (by 0.7 percentage points to 6.6 percent for BYETTA and by 0.5 percentage points to 6.9 percent for Lantus). In addition, BYETTA significantly reduced body weight compared to Lantus (17-pound difference between groups). After completion of three years of therapy, a four-week off-drug period followed to allow assessment of parameters of metabolic state including beta-cell function. Beta-cell function was assessed using a calculated disposition index (insulin secretion adjusted for insulin sensitivity). BYETTA increased insulin sensitivity by 39 percent and increased the disposition index, indicating an improvement in background beta-cell function. Lantus had no effect on insulin sensitivity or disposition index.

These findings suggest that with extended use, BYETTA treatment may help improve insulin production and help people with Type 2 diabetes better control their blood sugar levels.”

Amylin and Eli Lilly Press Release